Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK7 | Q8TDX7 | 11/20 | 0.48 |
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818010 | 0.92 | NEK7 (0.52) | NEK7BTKRETEGFRLCK | |
| SCHEMBL25822847 | 0.91 | NEK7 (0.60) | NEK7BTK | |
| SCHEMBL25793723 | 0.84 | NEK7 (0.61) | NEK7EGFRLCKSRCKDR | |
| SCHEMBL24096854 | 0.83 | NEK7 (0.65) | NEK7BTK | |
| SCHEMBL30320633 | 0.83 | NEK7 (0.65) | NEK7BTK | |
| SCHEMBL25793479 | 0.80 | NEK7 (0.61) | NEK7 | |
| SCHEMBL25817969 | 0.80 | SRC (0.51) | NEK7BTKRETEGFRLCK | |
| SCHEMBL25818025 | 0.80 | ITK (0.50) | NEK7BTKRETEGFRLCK | |
| SCHEMBL25818071 | 0.79 | NEK7 (0.56) | NEK7EGFRLCKSRCKDR | |
| SCHEMBL30500109 | 0.79 | NEK7 (0.62) | NEK7EGFRLCKSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | NEK7 1/4885BTK 988/4885RET 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.